⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6039254 | 0.95 | — | — | |
| SCHEMBL740941 | 0.71 | NPSR1 (0.32) | — | |
| SCHEMBL28296380 | 0.71 | NPSR1 (0.32) | — | |
| SCHEMBL8085814 | 0.70 | CYP2C19 (0.32) | — | |
| SCHEMBL30683839 | 0.70 | NPSR1 (0.34) | — | |
| SCHEMBL4598251 | 0.69 | — | — | |
| SCHEMBL6355124 | 0.69 | NPSR1 (0.33) | — | |
| SCHEMBL5722406 | 0.69 | FFAR3 (0.39) | — | |
| SCHEMBL20772092 | 0.69 | CYP4F2 (0.33) | — | |
| SCHEMBL15114643 | 0.68 | NPSR1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071199-B1 | Kinase inhibitors as therapeutic agents | ABBOTT GMBH & CCO. KG (DE) | 2006-07-04 | — | — | US | claimed |
| EP-1385524-A4 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2006-02-01 | — | — | EP | claimed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | claimed |
| EP-1212327-B8 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2004-02-25 | — | — | EP | claimed |
| EP-1385524-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | Abbott GmbH & Co. KG (DE) | 2004-02-04 | — | — | EP | claimed |
| US-6660744-B1 | Kinase inhibitors | ABBOTT GMBH & CO. KG (DE) | 2003-12-09 | — | — | US | claimed |
| EP-1212327-B1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AG (DE) | 2003-08-20 | — | — | EP | claimed |
| EP-1268481-A2 | KINASE INHIBITORS AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2003-01-02 | — | — | EP | claimed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | claimed |
| WO-2002080926-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | claimed |
| EP-1212327-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-12 | — | — | EP | claimed |
| WO-2001019828-A2 | KINASE INHIBITORS AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | claimed |
| WO-2001019829-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | claimed |
| US-7332497-B2 | As inhibitors of protein kinases | ABBOTT GMBH & CO KG (DE) | 2008-02-19 | — | — | US | disclosed |
| US-7071199-B1 | Kinase inhibitors as therapeutic agents | ABBOTT GMBH & CCO. KG (DE) | 2006-07-04 | — | — | US | disclosed |
| EP-1385524-A4 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2006-02-01 | — | — | EP | disclosed |
| WO-2002076986-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-03 | — | — | WO | disclosed |
| EP-1212327-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019829-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
| WO-2001019828-A2 | KINASE INHIBITORS AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |